Corporate Banner
Satellite Banner
Cell Culture
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Silencing Investor Concerns? Alnylam Achieves RNAi Milestone

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
Alnylam Pharmaceutical received milestone payment from GSK as part of their ongoing collaboration to utilize Alnylam’s RNA interference (RNAi) technology to develop GSK’s cell-culture based influenza vaccine.

While almost all other viral vaccines (e.g., mumps, measles, and polio) are currently produced via cell-culture, influenza vaccines have been resistant to cell-culture based manufacturing due to insufficient virus yield and quality. GSK hopes to utilize Alnylam’s VaxiRNA platform to overcome these challenges. The proprietary VaxiRNA technology utilizes RNAi to silence genes that limit or prevent the production of vaccine antigens.

As part of the collaboration, which was initiated in the fourth quarter of 2011, Alnylam receives R&D funding and milestone payments from GSK as well as royalties from any commercialized vaccine. GSK hopes to capitalize on Alnylam’s expertise to generate a commercially viable cell-culture based influenza vaccine that could be first to market in the United States.

The development of an innovative method to produce influenza vaccines has become a major initiative. Since the 1940s, influenza vaccines have been generated using chicken eggs. This process takes months and is difficult to scale-up. The recent H1N1 influenza pandemic highlighted these inadequacies and resulted in a renewed push for novel influenza vaccine manufacturing methodologies. A novel production process could also generate a vaccine that could be administered to individuals with egg allergies and decrease overall manufacturing costs. GSK expects to utilize its cell-culture method to enter this emerging market, but the company faces tough competition. For example, Novartis, in collaboration with the United States Department of Health and Human Services, is building a $1 billion facility in North Carolina that will house R&D and production facilities for a cell-culture based influenza vaccine program.

The milestone payment comes during a challenging time for Alnylam. Its ambitious “5x15” program hopes to develop RNAi therapies for five diseases with a high unmet need (e.g., hemophilia, hypercholesterolemia, refractory anemia) by 2015. Earlier this month, the company announced positive Phase I results concerning its therapy for transthyretin (TTR) amyloidosis, a progressive neurodegenerative disease caused by protein deposits, as well as promising pre-clinical results for its hemophilia treatment. These findings raised Alnylam’s stock price over 150% to $18.76 per share, but a pending lawsuit could cause shareholders to worry. Tekmira Pharmaceuticals Corporation, a Vancouver-based biotechnology company, alleges that Alnylam exploited their collaboration for commercial gain. The patent litigation, which heads to trial in October, threatens to hinder Alnylam’s ability to commercialize its 5x15 initiative. Alnylam is especially susceptible to any delay in 5x15-associated revenue since it has no marketed therapies. While Alnylam possibly struggles to transition from commercial platforms to therapies, a successful influenza vaccine methodology could alleviate investor concerns in the short-term.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Genetic Variability in Cell Bank Lots
Researchers working with cancer cells from the same cell bank acquired at the same time, found that the cells were genetically different.
3D Models May Yield Ovarian Cancer Insights
Researchers are developing new tools to decipher ovarian cancer developments through a 3D printing technology.
A Novel Cell Culture Model For Forensic Biology Experiments
Researchers have developed a new cell culture model which provides an efficient research tool in forensic biology.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
3D Printing Cartilage
3D bioprinting has successfully manufactured cartilage using bioink sourced from cow cartilage strands.
New Device can Study Electric Field Cancer Therapy
Microfluidic device allows study of electric field cancer therapy through low-intensity fields, preventing malignant cells spreading.
Scientists Culture Elusive Yellowstone Microbe
ORNL scientists have successfully isolated and cultured a Yellowstone sourced acidic hot-spring based microbe.
A 3D Paper-Based Microbial Fuel Cell
Researchers have developed a proof-of-concept 3D paper-based microbial fuel cell (MFC) that could take advantage of capillary action to guide the liquids through the MFC system and to eliminate the need for external power.
Just Gellin’: How To Grow Strong Muscles-On-A-Chip
USC researchers hope to usher in new treatments for patients with muscular dystrophy.
Lasers Carve the Path to Tissue Engineering
A new technique, developed at EPFL, combines microfluidics and lasers to guide cells in 3D space, overcoming major limitations to tissue engineering.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!